EMP technical briefing seminar, Geneva 6 November 2014 The Global Platform on Innovation and Access to medical products and technologies Claudia Nannei 1
Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property Its aim: Promote new thinking on innovation and access to medicines and Secure an enhanced and sustainable basis for needs-driven essential health research and development relevant to diseases that disproportionately affect developing countries. 2
Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property How? Offering an holistic approach to the issue of innovation for medical technologies to address diseases disproportionally affecting developing countries and proposing specific actions to: Set, prioritize and promote research; Foster and build innovation capacity; Promote technology transfer and local production of medical products; Improve access to medical products; Promote the management and application of intellectual property rights to improve public health; Mobilize resources for research and development relevant to this area and Monitor and evaluate the progress in all these areas. 3
How can national governments coordinate their policies for the needed innovation to take place? Innovation for health is a complex issue that requires multisectorial approach and coordination Innovation involves government policies and legislation in public health, international trade, national and international procurement, industrial development, finance, education, science and technology, international relations and cooperation 4
A simple mapping tool National assessment tool for public health, innovation and intellectual property (NAT): mapping health R&D policies, system, infrastructure, human resources and financing; access to know how and technology transfer, local production capacity for pharmaceuticals; intellectual property management; regulation and procurement of medical products and technologies, incentives for health innovation, health delivery infrastructures, trade agreements, information monitoring systems. 5
WHY? Identify areas for improvement, Identify contradictory policies, Identify synergies Create necessary coordination among agencies => ensure policy coherence 6
GSPA-PHI: the mandate Element 8 Establishing monitoring and reporting systems Specific action 8.1 a requires WHO and Member States to Establish systems to monitor performance and progress of the implementation of each element of the GSPA 7
Global Platform on Innovation and Access 8
What is it? New web-based platform for governments, intergovernmental organizations, public health researchers, NGOs and other stakeholders Provides user-friendly, reliable and regularly updated information on innovation and access to medical products and technologies and GSPA-PHI implementation Unique point to store, access, analyse and share information collected through the NAT; Repository of relevant policies and legislations on the areas contributing to innovation Networking tool through its virtual forum on innovation 9
Expected outcomes GPIA will ensure: Better design and management of regional and national health research and innovation systems; More efficient innovation based on combined expertise which has been traditionally working in isolation; Policy coherence More effective and targeted capacity-building programs, tailored to identified national gaps and needs; and, Creation of a visible and responsible global community working together to facilitate innovation for and access to medical products and technologies. 10
Its structure 11
The Platform : its functions Promoting Innovation and Access through Global Strategies GPIA 12
Current data sources Pharmaceutical Sector Country Profile (PCP) Regional Platform on Access and Innovation for Health Technologies 13
Planned data sources Global Health R&D Observatory New PCP Other WHO databases (NRA indicators, GHO ) External links (WIPO Re:Search?) 14
The Platform : the development process 1 st version Information hub Beta version Repository Innovation forum Validation phase Feedback Adjustments Evolution 2, 3 n th version maintenance 15
THANK YOU!!! And stay tuned for future developments! Claudia Nannei EMP/PHI nanneic@who.int 16